X4 Pharmaceuticals Inc $ 9.74 -0.01 (-0.1%)
Volume:
122,240
Avg Vol (1m):
104,821
Market Cap $:
158.63 Mil
Enterprise Value $:
100.79 Mil
PE Ratio:
0.00
PB Ratio:
2.18
Financial Strength | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.87 | ||
| Debt-to-Equity | 0.35 | ||
| Debt-to-EBITDA | -0.6 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | -0.19 | ||
| Beneish M-Score | -2.83 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -1773.27 | ||
| Net Margin % | -1818.93 | ||
| ROE % | -52.3 | ||
| ROA % | -39 | ||
| ROC (Joel Greenblatt) % | -1386.4 | ||
| 3-Year EBITDA Growth Rate | 41.4 | ||
| 3-Year EPS without NRI Growth Rate | 53.8 |
XFOR
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.18 | ||
| PS Ratio | 64.92 | ||
| EV-to-EBIT | -1.94 | ||
| EV-to-EBITDA | -1.96 | ||
| EV-to-Revenue | 33.59 | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 7.13 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -159 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.12 | ||
| Earnings Yield (Greenblatt) % | -51.63 |